/PLRZ
PLRZ Stock - Polyrizon Ltd.
Healthcare|BiotechnologyNASDAQ
$9.43-6.73%
$0.68 (-6.73%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $10.37
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PLRZ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.34 – $9.52
TARGET (TP)$10.84
STOP LOSS$8.68
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-4.50
52W High$4200.00
52W Low$2.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-118,000 | $-4,000 | $-5,000 | $-6,000 | $-1,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,302,000 | $-635,000 | $-895,000 | $-703,000 | $-72,000 |
| Net Income | $-1,545,000 | $-600,000 | $-779,000 | $-711,000 | $-73,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-134.14 | $0.00 | $0.00 | $0.00 | $0.00 |
Company Overview
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PLRZLoading earnings data...
Latest News
Polyrizon Submits Pre-RFD To FDA For Its PL-16 Viral Blocker Designed To Reduce Exposure To Influenza And Cold Viruses
📈 PositiveBenzinga•Dec 19, 2025, 01:23 PM
Polyrizon Reports Preclinical Results For Intranasal Naloxone Hydrogel Showing Strong Permeation Kinetics, Stability & Mucoadhesion
📈 PositiveBenzinga•Dec 11, 2025, 01:23 PM
Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker, Paving Way For 2026 Clinical Trials
📈 PositiveBenzinga•Dec 8, 2025, 01:55 PM
Polyrizon Announces New Preclinical Data Showing Proprietary Naloxone Hydrogel Adheres To Nasal Tissue Longer Than Approved And Marketed Intranasal Naloxone Spray Product
📈 PositiveBenzinga•Dec 3, 2025, 02:29 PM
Polyrizon Shares Resume Trade
➖ NeutralBenzinga•Dec 2, 2025, 05:27 PM
Polyrizon Shares Halted On Circuit Breaker To The Upside, Stock Now Up 132.28%
📈 PositiveBenzinga•Dec 2, 2025, 05:23 PM
Polyrizon Shares Halted On Circuit Breaker To The Upside, Stock Now Up 127.22%
📈 PositiveBenzinga•Dec 2, 2025, 02:44 PM
Polyrizon shares are trading higher after the company announced it completed a manufacturing upscaling milestone for its proprietary nasal-spray product platform.
📈 PositiveBenzinga•Dec 2, 2025, 01:43 PM
Polyrizon Completes Manufacturing Upscaling Milestone For Its Proprietary Nasal-Spray Product Platform
📈 PositiveBenzinga•Dec 2, 2025, 12:57 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 27, 2025, 12:50 AM
Polyrizon shares are trading lower after the company announced a 1-for-6 reverse stock split.
📉 NegativeBenzinga•Nov 25, 2025, 06:32 PM
Polyrizon Files For Mixed Shelf Of Upto $50M
➖ NeutralBenzinga•Nov 7, 2025, 09:21 PM
UPDATE: Polyrizon's Nasal Gel PL-16 Confirms In-Vitro Protection Against H1N1 Via Reversible Physical Barrier Mechanism
📈 PositiveBenzinga•Nov 6, 2025, 02:00 PM
Polyrizon Releases Pre-Clinical Results For Its PL-14 Allergy Blocker Showing That PL-14 Effectively Blocked The Penetration Of Der P 1, A Major House Dust Mite Allergen
📈 PositiveBenzinga•Oct 6, 2025, 12:24 PM
Polyrizon shares are trading higher after the company announced the submission of its full pre-submission package to the FDA for its PL-14 product.
📈 PositiveBenzinga•Sep 19, 2025, 01:01 PM
Polyrizon Submits Full Pre-Sub Package To FDA For PL-14 Product, Designed To Help Individuals Suffering From Nasal Allergies
📈 PositiveBenzinga•Sep 19, 2025, 12:17 PM
Polyrizon shares are trading higher after the company announced preclinical results for its PL-14 Allergy Blocker.
📈 PositiveBenzinga•Sep 12, 2025, 12:38 PM
Polyrizon Reports Positive Preclinical Results For PL-14 Intranasal Allergy Blocker; Achieves 60% Targeted Nasal Deposition, Advancing Toward Clinical Trials
📈 PositiveBenzinga•Sep 12, 2025, 11:29 AM
Polyrizon retains Nasdaq listing following hearings panel
📈 PositiveSeeking Alpha•Jul 15, 2025, 12:37 PM
Polyrizon receives Nasdaq notification regarding minimum bid requirements
📉 NegativeSeeking Alpha•Apr 11, 2025, 08:43 PM
Frequently Asked Questions about PLRZ
What is PLRZ's current stock price?
Polyrizon Ltd. (PLRZ) is currently trading at $9.43 per share. The stock has moved -6.73% today.
What is the analyst price target for PLRZ?
No analyst price targets are currently available for this stock.
What sector is Polyrizon Ltd. in?
Polyrizon Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PLRZ's market cap?
Polyrizon Ltd. has a market capitalization of $0.01 billion, making it a small-cap company.
Does PLRZ pay dividends?
No, Polyrizon Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIM
AIM ImmunoTech Inc.
$1.42
Mkt Cap: $0.0B
CYCN
Cyclerion Therapeutics, Inc.
$1.45
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
NBY
NovaBay Pharmaceuticals, Inc.
$5.30
Mkt Cap: $0.0B
PMCB
PharmaCyte Biotech, Inc.
$0.86
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
RADX
Radiopharm Theranostics Limited
$5.19
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
XTLB
XTL Biopharmaceuticals Ltd.
$0.82
Mkt Cap: $0.0B
Explore stocks similar to PLRZ for comparison